Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MVD | P53602 | 1/20 | 0.43 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.43 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 8/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | EYA2 | O00167 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycylsarcosine SCHEMBL4161366 | 0.98 | MVD (0.42) | MVDGLRA1SLC6A9OR51E2AOC3 | |
| Glycylsarcosine SCHEMBL27640673 | 0.83 | MVD (0.37) | MVDGLRA1SLC6A9OR51E2AOC3 | |
| SCHEMBL28427604 | 0.81 | PHF8 (0.41) | MVDGLRA1SLC6A9OR51E2TDP1 | |
| SCHEMBL22764472 | 0.80 | AOC3 (0.36) | GLRA1SLC6A9OR51E2AOC3TDP1 | |
| SCHEMBL13644299 | 0.80 | AOC3 (0.36) | GLRA1SLC6A9OR51E2AOC3GAA | |
| SCHEMBL22625776 | 0.79 | CA12 (0.34) | MVDGLRA1SLC6A9OR51E2TDP1 | |
| SCHEMBL1767618 | 0.78 | MVD (0.42) | MVDTDP1EYA2APPACE | |
| SCHEMBL24065976 | 0.78 | MVD (0.36) | MVDGLRA1SLC6A9OR51E2TDP1 | |
| SCHEMBL1712304 | 0.77 | MVD (0.44) | MVDTDP1EYA2APPACE | |
| SCHEMBL1712300 | 0.77 | MVD (0.44) | MVDTDP1EYA2APPACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 436 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117661179-A | Antibacterial fabric, preparation method thereof and garment with rare earth magnetic particles | 广州平衡态健康产业科技有限公司 | 2024-03-08 | — | — | CN | claimed |
| US-20240009321-A1 | IMMUNOGENIC NANOVESICLES FOR CANCER IMMUNOTHERAPY | NATIONAL INSTITUTES OF HEALTH | 2024-01-11 | — | — | US | claimed |
| US-20230414699-A1 | TREATMENT OF DERMATOLOGICAL CONDITIONS | MC2 THERAPEUTICS LTD (GB) | 2023-12-28 | — | — | US | claimed |
| EP-4237008-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | Elucida Oncology, Inc. (US) | 2023-09-06 | — | — | EP | claimed |
| EP-4225293-A1 | TREATMENT OF DERMATOLOGICAL CONDITIONS | MC2 Therapeutics Limited (GB) | 2023-08-16 | — | — | EP | claimed |
| CN-116322671-A | Treatment of dermatological disorders | MC2疗法有限公司 | 2023-06-23 | — | — | CN | claimed |
| CN-115192578-A | Preparation of mixed micelle carrying quercetin and nintedanib | 山东大学齐鲁医院 | 2022-10-18 | — | — | CN | claimed |
| WO-2022115488-A1 | IMMUNOGENIC NANOVESICLES FOR CANCER IMMUNOTHERAPY | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2022-06-02 | — | — | WO | claimed |
| CN-111423529-B | Free radical photopolymerization initiation system based on amino acid derivatives and method for initiating free radical photopolymerization by using same | 海南师范大学 | 2022-05-17 | — | — | CN | claimed |
| WO-2022093800-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. (US) | 2022-05-05 | — | — | WO | claimed |
| CN-101340913-A | Prophylactic or therapeutic agent for pancreatic cancer, ovarian cancer or liver cancer comprising novel water-soluble prodrug | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2009-01-07 | — | — | CN | claimed |
| EP-1938823-A1 | AGENT FOR PREVENTING OR TREATING PANCREAS CANCER, OVARY CANCER OR LIVER CANCER CONTAINING NOVEL WATER-SOLUBLE PRODRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-07-02 | — | — | EP | claimed |
| US-20080015157-A1 | Novel Water-Soluble Prodrugs | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-01-17 | — | — | US | claimed |
| EP-1854792-A1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-11-14 | — | — | EP | claimed |
| CN-1964979-A | Novel water-soluble prodrug | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2007-05-16 | — | — | CN | claimed |
| US-20070066541-A1 | Compositions and methods for the intraocular transport of therapeutic agents | ALLERGAN, INC. (US) | 2007-03-22 | — | — | US | claimed |
| EP-1757609-A1 | NOVEL WATER-SOLUBLE PRODRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-02-28 | — | — | EP | claimed |
| US-6429220-B1 | COMPRISES AN ISOTHIAZOLONE COMPOUND AND AN AMINOCARBOXYLIC ACID | KURITA WATER INDUSTRIES LTD. (JP) | 2002-08-06 | — | — | US | claimed |
| US-4427762-A | DEVELOPMENT WITH ALKALINE DEVELOPER MIXTURE | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1984-01-24 | — | — | US | claimed |
| EP-0082015-A1 | Method of forming an image with a photographic cuprous halide material | KONICA CORPORATION (JP) | 1983-06-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240009321-A1 | IMMUNOGENIC NANOVESICLES FOR CANCER IMMUNOTHERAPY | SGMS1, SGMS2, SMPD3 | MVD 2091/4885GLRA1 4452/4885SLC6A9 3437/4885 |
| US-20080015157-A1 | Novel Water-Soluble Prodrugs | ADH1A, ADH1C, SLC43A1 | MVD 4073/4885GLRA1 762/4885SLC6A9 113/4885 |
| US-20070066541-A1 | Compositions and methods for the intraocular transport of therapeutic agents | SLC47A2, SLC47A1, SLC2A1 | MVD 2759/4885GLRA1 1551/4885SLC6A9 124/4885 |
| US-20230414699-A1 | TREATMENT OF DERMATOLOGICAL CONDITIONS | PRKDC, DPM1, MMP8 | MVD 2323/4885GLRA1 4582/4885SLC6A9 4034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.